Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma

1 Aug 2025

Abstract excerpt

Background HRAS mutations define a distinct biologic subset of head and neck squamous-cell carcinoma (HNSCC). There are limited data regarding HRAS -mutant (mut) tumors' sensitivity to immunotherapy. We sought to evaluate the mutational landscape and transcriptional profile, as well as analyze the tumor microenvironment (TME) of HRAS -mut tumors to provide the conceptual framework for combinatorial treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Head and Neck Cancer Studies
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40803018
DOI: 10.1016/j.esmoop.2025.105538

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinomaPMID 40803018Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Semantic proximity Read ↗

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell CancerSemantic proximity Read ↗

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

The Single-Cell Landscape of Peripheral and Tumor-infiltrating Immune Cells in HPV- HNSCCSemantic proximity Read ↗

Immune landscape in molecular subtypes of human papillomavirus‐negative head and neck cancerSemantic proximity Read ↗

The head and neck cancer genome in the era of immunotherapy.Semantic proximity Read ↗

Evaluation of Alcohol, Tobacco, and HPV’s Synergistic regulation of Head and Neck Squamous Cell Carcinoma Treatment Response to PD-L1 Checkpoint Inhibitor TreatmentSemantic proximity Read ↗

MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.Semantic proximity Read ↗

Molecular Aspects of Head and Neck Cancer Therapy.Semantic proximity Read ↗

Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironmentsSemantic proximity Read ↗

Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.